Goh Keow Lin 4

4 · Tevogen Bio Holdings Inc. · Filed Jul 10, 2026

AI-generated summary of this filing

Updated Jul 10, 2026

Tevogen (TVGN) Director Goh Keow Lin Receives 40,000-Share Award

What Happened

Goh Keow Lin, a director of Tevogen Bio Holdings, was granted 40,000 restricted shares on July 10, 2026. The transaction is reported as an award/grant (code A) at a reported price of $0.00, meaning no cash was exchanged at grant.

Key Details

Transaction date: 2026-07-10; transaction type: Award/Grant (A).
Shares granted: 40,000; reported acquisition price: $0.00 (no cash paid).
Shares owned after transaction: Not disclosed in the filing.
Vesting/conditions (footnote): The grant is restricted stock under Tevogen’s 2024 Omnibus Incentive Plan and vests in three equal installments upon the earlier of (a) the 1st anniversary and the company having $50M aggregate revenue since the grant, (b) the 2nd anniversary and $100M aggregate revenue, and (c) the 3rd anniversary and $150M aggregate revenue — provided the director remains in service on each vesting date.
Filing timeliness: Report filed with a period/report date of 2026-07-10; no late filing indicated.

Context

Restricted stock grants are compensation awards, not open-market purchases or sales; they do not require an immediate cash outlay and vest only if service and revenue milestones are met. Such grants align insider compensation with company performance but should not be read alone as a market sentiment signal.

Form 4

Period: 2026-07-10

Director

Transactions

Footnotes (1)

[F1]Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.

Signature

/s/ Kirti Desai, Attorney-in-Fact|2026-07-10

1 file